Knowledge is power when living with prostate cancer.
Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.Already a subscriber? Sign in here
Adding Zytiga, Prednisone to ADT Improves Outcomes for Newly Diagnosed, High-risk Metastatic Prostate Cancer Patients
Newly diagnosed men with high-risk metastatic hormone-naive prostate cancer (mHNPC) lived significantly healthier, longer lives when doctors added Zytiga (abiraterone acetate) and prednisone to their androgen deprivation therapy (ADT), according to results from the Phase 3 LATITUDE trial. The trial (NCT01715285), designed by Belgian pharmaceutical giant Janssen, assessed the safety and effectiveness of the triple combination compared to